Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept
Supplemental Data
Revised supplemental data (.pdf, 868 KB)
- Revised supplemental data